This digest covers some of the most relevant progress in malaria drug discovery published
between 2010 and 2012. There is an urgent need to develop new antimalarial drugs. Such …

Early data emerging from the first phase 3 trial of a malaria vaccine are raising hopes that a
licensed vaccine will soon be available for use in endemic countries, but given the relatively …

The resistance of malaria parasites to existing drugs carries on growing and progressively
limiting our ability to manage this severe disease and finally lead to a massive global health …

Malaria—a parasite vector-borne disease—is a global health problem, and Plasmodium
falciparum has proven to be the deadliest among Plasmodium spp., which causes malaria in …

Plasmodium parasites are the causative agent of human malaria, and the development of a
highly effective vaccine against infection, disease and transmission remains a key priority. It …

Understanding the life cycle of Plasmodium vivax is fundamental for developing strategies
aimed at controlling and eliminating this parasitic species. Although advances in omic …

Investigation of the diversity of malaria parasite antigens can help prioritize and validate
them as vaccine candidates and identify the most common variants for inclusion in vaccine …

After more than 50 years of intensive research and development, only one malaria vaccine
candidate,“RTS, S,” has progressed to Phase 3 clinical trials. Despite only partial efficacy …

The Experiment Must Continue is a beautifully articulated ethnographic history of medical
experimentation in East Africa from 1940 through 2014. In it, Melissa Graboyes combines …

Despite global efforts to control malaria, the illness remains a significant public health threat.
Currently, there is no licensed vaccine against malaria, but an efficacious vaccine would …